#	Pagina
attuale pagina	/open-h2020/projects/212939/index.html

Opendata, web and dolomites

REPO-TRIAL SIGNED

An in silico-based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a mechanism-based patient cohort with predominant cerebro-cardiovascular phenotypes

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

REPO-TRIAL project word cloud

Explore the words cloud of the REPO-TRIAL project. It provides you a very rough idea of what is the project "REPO-TRIAL" about.

patient reducing disturbance precision exclusive innovative equilibria applicable simulation systematic drug cerebro animal platform vagueness reduce facilitated time reduces meta patients panel phenotype choose discovered biomarker biomedical generates efficacy pendant frame mechanistically symptom scientifically rapid stratified diagnostics translation unrealistic reviews of benefit size describe self our diseases confirmatory silico mechanistic enhances models trials repositionings repurposing cohort de chosen classes experimentation definitions biomolecular risks prcts org innovate industrial identifies cardiovascular competitiveness gov disease validate regulation apparent novo medicine phenotypes drugs validation generally trial clinical preclinical organ putatively virtual computer randomised clinicaltrials

Project "REPO-TRIAL" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITEIT MAASTRICHT Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD website: http://www.maastrichtuniversity.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	https://repo-trial.eu/
Total cost	5˙536˙775 €
EC max contribution	5˙536˙772 € (100%)
Programme	1. H2020-EU.3.1.5. (Methods and data)
Code Call	H2020-SC1-2017-CNECT-2
Funding Scheme	RIA
Starting year	2018
Duration (year-month-day)	from 2018-02-01 to 2023-01-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITEIT MAASTRICHT UNIVERSITEIT MAASTRICHT Organization address address: Minderbroedersberg 4-6 city: MAASTRICHT postcode: 6200 MD website: http://www.maastrichtuniversity.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (MAASTRICHT)	coordinator	1˙270˙089.00
2	UNIVERSITY OF NEWCASTLE UPON TYNE UNIVERSITY OF NEWCASTLE UPON TYNE Organization address address: KINGS GATE city: NEWCASTLE UPON TYNE postcode: NE1 7RU website: http://www.ncl.ac.uk/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (NEWCASTLE UPON TYNE)	participant	844˙728.00
3	TECHNISCHE UNIVERSITAET MUENCHEN TECHNISCHE UNIVERSITAET MUENCHEN Organization address address: Arcisstrasse 21 city: MUENCHEN postcode: 80333 website: www.tu-muenchen.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUENCHEN)	participant	742˙045.00
4	UNIVERSITAETSKLINIKUM ESSEN UNIVERSITAETSKLINIKUM ESSEN Organization address address: HUFELANDSTRASSE 55 city: ESSEN postcode: 45147 website: www.uk-essen.de/frauenklinik/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (ESSEN)	participant	597˙565.00
5	MEDIZINISCHE HOCHSCHULE HANNOVER MEDIZINISCHE HOCHSCHULE HANNOVER Organization address address: Carl-Neuberg-Strasse 1 city: HANNOVER postcode: 30625 website: www.mh-hannover.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HANNOVER)	participant	550˙722.00
6	UNIVERSITAIR MEDISCH CENTRUM UTRECHT UNIVERSITAIR MEDISCH CENTRUM UTRECHT Organization address address: HEIDELBERGLAAN 100 city: UTRECHT postcode: 3584 CX website: www.umcutrecht.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (UTRECHT)	participant	550˙722.00
7	Concentris Research Management GmbH Concentris Research Management GmbH Organization address address: Ludwigstr. 4 city: Fürstenfeldbruck postcode: D-82256 website: www.concentris.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (Fürstenfeldbruck)	participant	355˙026.00
8	SOMALOGIC LIMITED SOMALOGIC LIMITED Organization address address: 4 STUDLEY COURT GUILDFORD ROAD city: CHOBHAM postcode: GU24 8EB website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (CHOBHAM)	participant	342˙964.00
9	BIOCRATES LIFE SCIENCES AG BIOCRATES LIFE SCIENCES AG Organization address address: EDUARD BODEM GASSE 8 1 STOCK city: INNSBRUCK postcode: 6020 website: www.biocrates.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (INNSBRUCK)	participant	157˙789.00
10	MUCKE HERMANN MUCKE HERMANN Organization address address: ENENKELSTR. 28/32 city: WIEN postcode: 1160 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (WIEN)	participant	125˙122.00
11	SYDDANSK UNIVERSITET SYDDANSK UNIVERSITET Organization address address: CAMPUSVEJ 55 city: ODENSE M postcode: 5230 website: www.sdu.dk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DK (ODENSE M)	participant	0.00

Map

Project objective

Our programme will develop an innovative in-silico based approach to improve the efficacy and precision of drug repurposing trials. We have chosen drug repurposing as it has the shortest time for clinical validation and translation. Validation of all putatively de novo discovered drug repositionings within the time-frame of this programme would be unrealistic. To improve efficacy and precision, and to adopt our computer simulation parameters and models, we choose a systems medicine based in-silico approach that identifies mechanistically related disease phenotypes and, as a result, a virtual patient cohort. We then validate this in-silico drug repurposing via high precision clinical trials in patients with cerebro-cardiovascular phenotypes stratified using an exclusive mechanistic biomarker panel. We thus innovate two biomedical product classes, drugs and diagnostics. With this we will establish generally applicable in silico trials for other mechanistically related or defined disease phenotypes, for which size, duration, and risks will be reduced and precision increased. This generates rapid patient benefit, reduces drug development costs as well as risks, and enhances industrial competitiveness. Scientifically, we will contribute to reducing the uncertainty and vagueness of many of our current disease definitions that describe a symptom or apparent phenotype in an organ rather than defining diseases mechanistically as disturbance of self-regulation equilibria of biomolecular processes. Finally, we will reduce animal experimentation and animal numbers in general by applying a preclinical randomised confirmatory trial (pRCTs) concept and preclinical systematic reviews and meta-analyses facilitated by our open access pre-clinicaltrials.org platform, a pendant to clinicaltrials.gov.

Deliverables

List of deliverables.
Project brochure and professional templates	Websites, patent fillings, videos etc.	2019-11-06 13:06:26
Software for detection of pathway co-enrichment for extracting of patient(group)-specific pathways also enriched in target sites of effective drugs	Other	2019-11-06 13:06:20
Communication and dissemination plan	Websites, patent fillings, videos etc.	2019-11-06 13:06:11
Diseasome 2.0 network	Other	2019-11-06 13:06:12

Take a look to the deliverables list in detail: detailed list of REPO-TRIAL deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	Mahmoud H. Elbatreek, Mayra P. Pachado, Antonio Cuadrado, Karin Jandeleit-Dahm, Harald H.H.W. Schmidt Reactive Oxygen Comes of Age: Mechanism-Based Therapy of Diabetic End-Organ Damage published pages: 312-327, ISSN: 1043-2760, DOI: 10.1016/j.tem.2019.02.006	Trends in Endocrinology & Metabolism 30/5	2019-09-26
2019	Ana I. Casas, Pamela W.M. Kleikers, Eva Geuss, Friederike Langhauser, Thure Adler, Dirk H. Busch, Valerie Gailus-Durner, Martin HrabÃª de Angelis, Javier Egea, Manuela G. Lopez, Christoph Kleinschnitz, Harald H.H.W. Schmidt Calcium-dependent blood-brain barrier breakdown by NOX5 limits postreperfusion benefit in stroke published pages: 1772-1778, ISSN: 0021-9738, DOI: 10.1172/jci124283	Journal of Clinical Investigation 129/4	2019-09-26
2019	Ana I. Casas, Ahmed A. Hassan, Simon J. Larsen, Vanessa Gomez-Rangel, Mahmoud Elbatreek, Pamela W. M. Kleikers, Emre Guney, Javier Egea, Manuela G. LÃ³pez, Jan Baumbach, Harald H. H. W. Schmidt From single drug targets to synergistic network pharmacology in ischemic stroke published pages: 7129-7136, ISSN: 0027-8424, DOI: 10.1073/pnas.1820799116	Proceedings of the National Academy of Sciences 116/14	2019-09-26
2018	Joaquim Aguirre-Plans, Janet PiÃ±ero, JÃ¶rg Menche, Ferran Sanz, Laura Furlong, Harald Schmidt, Baldo Oliva, Emre Guney Proximal Pathway Enrichment Analysis for Targeting Comorbid Diseases via Network Endopharmacology published pages: 61, ISSN: 1424-8247, DOI: 10.3390/ph11030061	Pharmaceuticals 11/3	2019-09-26
2018	Simon J Larsen, Richard RÃ¶ttger, Harald HÂ HÂ W Schmidt, Jan Baumbach E. coli gene regulatory networks are inconsistent with gene expression data published pages: 85-92, ISSN: 0305-1048, DOI: 10.1093/nar/gky1176	Nucleic Acids Research 47/1	2019-09-26

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REPO-TRIAL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REPO-TRIAL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.5.)

EUCANCan (2019)

EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.

iReceptor Plus (2019)

ARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T-CELL RECEPTOR SEQUENCING DATA REPOSITORIES FOR ENABLING IMPROVED PERSONALIZED MEDICINE AND IMMUNOTHERAPY